nodes	percent_of_prediction	percent_of_DWPC	metapath
Theophylline—CYP1A1—kidney cancer	0.246	1	CbGaD
Theophylline—CYP1B1—Erlotinib—kidney cancer	0.059	0.131	CbGbCtD
Theophylline—CYP1B1—Paclitaxel—kidney cancer	0.054	0.12	CbGbCtD
Theophylline—CYP1B1—Doxorubicin—kidney cancer	0.0291	0.0646	CbGbCtD
Theophylline—CYP1A1—Erlotinib—kidney cancer	0.0259	0.0575	CbGbCtD
Theophylline—CYP2D6—Temsirolimus—kidney cancer	0.0254	0.0565	CbGbCtD
Theophylline—CYP3A4—Everolimus—kidney cancer	0.0239	0.0531	CbGbCtD
Theophylline—CYP2C8—Pazopanib—kidney cancer	0.021	0.0465	CbGbCtD
Theophylline—CYP1A2—Pazopanib—kidney cancer	0.0162	0.036	CbGbCtD
Theophylline—CYP3A4—Temsirolimus—kidney cancer	0.0162	0.0359	CbGbCtD
Theophylline—CYP2C9—Capecitabine—kidney cancer	0.0152	0.0338	CbGbCtD
Theophylline—CYP2C8—Erlotinib—kidney cancer	0.015	0.0332	CbGbCtD
Theophylline—CYP2C8—Paclitaxel—kidney cancer	0.0137	0.0304	CbGbCtD
Theophylline—CYP2D6—Pazopanib—kidney cancer	0.0134	0.0297	CbGbCtD
Theophylline—CYP2C8—Sorafenib—kidney cancer	0.0122	0.027	CbGbCtD
Theophylline—CYP1A2—Erlotinib—kidney cancer	0.0116	0.0257	CbGbCtD
Theophylline—CYP2C9—Paclitaxel—kidney cancer	0.00955	0.0212	CbGbCtD
Theophylline—CYP2D6—Erlotinib—kidney cancer	0.00954	0.0212	CbGbCtD
Theophylline—CYP1A2—Sorafenib—kidney cancer	0.00941	0.0209	CbGbCtD
Theophylline—CYP3A4—Pazopanib—kidney cancer	0.0085	0.0189	CbGbCtD
Theophylline—CYP2C9—Sorafenib—kidney cancer	0.00848	0.0188	CbGbCtD
Theophylline—CYP2D6—Sorafenib—kidney cancer	0.00775	0.0172	CbGbCtD
Theophylline—CYP2D6—Vinblastine—kidney cancer	0.00766	0.017	CbGbCtD
Theophylline—CYP3A4—Erlotinib—kidney cancer	0.00606	0.0135	CbGbCtD
Theophylline—CYP3A4—Paclitaxel—kidney cancer	0.00555	0.0123	CbGbCtD
Theophylline—CYP3A4—Sorafenib—kidney cancer	0.00493	0.0109	CbGbCtD
Theophylline—CYP3A4—Vinblastine—kidney cancer	0.00487	0.0108	CbGbCtD
Theophylline—CYP3A4—Vincristine—kidney cancer	0.00479	0.0106	CbGbCtD
Theophylline—CYP2D6—Doxorubicin—kidney cancer	0.0047	0.0104	CbGbCtD
Theophylline—CYP3A4—Sunitinib—kidney cancer	0.00399	0.00887	CbGbCtD
Theophylline—Caffeine—RYR1—kidney cancer	0.00307	0.61	CrCbGaD
Theophylline—CYP3A4—Doxorubicin—kidney cancer	0.00299	0.00664	CbGbCtD
Theophylline—CYP1A2—urine—kidney cancer	0.00212	0.0499	CbGeAlD
Theophylline—CYP2C9—urine—kidney cancer	0.00201	0.0473	CbGeAlD
Theophylline—CYP2E1—urine—kidney cancer	0.0019	0.0448	CbGeAlD
Theophylline—CYP3A4—urine—kidney cancer	0.00153	0.0361	CbGeAlD
Theophylline—CYP2D6—urine—kidney cancer	0.00151	0.0355	CbGeAlD
Theophylline—PDE4D—cortex of kidney—kidney cancer	0.0015	0.0354	CbGeAlD
Theophylline—Caffeine—PIK3CA—kidney cancer	0.00147	0.292	CrCbGaD
Theophylline—ADA—renal system—kidney cancer	0.00145	0.0342	CbGeAlD
Theophylline—SLC22A7—renal system—kidney cancer	0.00131	0.0308	CbGeAlD
Theophylline—SLC22A7—kidney—kidney cancer	0.00126	0.0298	CbGeAlD
Theophylline—HDAC2—nephron tubule—kidney cancer	0.00124	0.0292	CbGeAlD
Theophylline—SLC22A7—cortex of kidney—kidney cancer	0.00123	0.029	CbGeAlD
Theophylline—PDE5A—renal system—kidney cancer	0.0012	0.0283	CbGeAlD
Theophylline—ADORA2A—gonad—kidney cancer	0.00118	0.0279	CbGeAlD
Theophylline—ADORA1—renal system—kidney cancer	0.00114	0.0268	CbGeAlD
Theophylline—HDAC2—renal system—kidney cancer	0.00113	0.0265	CbGeAlD
Theophylline—ADORA1—kidney—kidney cancer	0.0011	0.026	CbGeAlD
Theophylline—HDAC2—kidney—kidney cancer	0.00109	0.0256	CbGeAlD
Theophylline—PDE5A—gonad—kidney cancer	0.00108	0.0254	CbGeAlD
Theophylline—ADORA1—cortex of kidney—kidney cancer	0.00107	0.0253	CbGeAlD
Theophylline—HDAC2—cortex of kidney—kidney cancer	0.00106	0.025	CbGeAlD
Theophylline—PDE3A—cardiac atrium—kidney cancer	0.00105	0.0247	CbGeAlD
Theophylline—ADORA1—cardiac atrium—kidney cancer	0.00102	0.024	CbGeAlD
Theophylline—HDAC2—gonad—kidney cancer	0.00101	0.0238	CbGeAlD
Theophylline—HDAC2—Sirolimus—Everolimus—kidney cancer	0.000795	0.2	CbGdCrCtD
Theophylline—HDAC2—Sirolimus—Temsirolimus—kidney cancer	0.000795	0.2	CbGdCrCtD
Theophylline—HDAC2—Temsirolimus—Everolimus—kidney cancer	0.000795	0.2	CbGdCrCtD
Theophylline—HDAC2—Everolimus—Temsirolimus—kidney cancer	0.000795	0.2	CbGdCrCtD
Theophylline—CYP1B1—nephron tubule—kidney cancer	0.000794	0.0187	CbGeAlD
Theophylline—PDE4B—cortex of kidney—kidney cancer	0.000793	0.0187	CbGeAlD
Theophylline—HDAC2—Gefitinib—Erlotinib—kidney cancer	0.000792	0.2	CbGdCrCtD
Theophylline—PDE4B—gonad—kidney cancer	0.000756	0.0178	CbGeAlD
Theophylline—PDE4B—cardiac atrium—kidney cancer	0.000755	0.0178	CbGeAlD
Theophylline—CYP1B1—renal system—kidney cancer	0.000722	0.017	CbGeAlD
Theophylline—CYP1B1—kidney—kidney cancer	0.000698	0.0165	CbGeAlD
Theophylline—CYP1B1—cortex of kidney—kidney cancer	0.00068	0.016	CbGeAlD
Theophylline—CYP1B1—gonad—kidney cancer	0.000648	0.0153	CbGeAlD
Theophylline—CYP2C8—renal system—kidney cancer	0.000553	0.013	CbGeAlD
Theophylline—CYP2C8—kidney—kidney cancer	0.000535	0.0126	CbGeAlD
Theophylline—CYP1A2—renal system—kidney cancer	0.000518	0.0122	CbGeAlD
Theophylline—CYP2E1—nephron tubule—kidney cancer	0.000512	0.0121	CbGeAlD
Theophylline—CYP1A1—renal system—kidney cancer	0.00051	0.012	CbGeAlD
Theophylline—CYP1A1—kidney—kidney cancer	0.000494	0.0116	CbGeAlD
Theophylline—CYP2E1—renal system—kidney cancer	0.000466	0.011	CbGeAlD
Theophylline—CYP1A1—cardiac atrium—kidney cancer	0.000457	0.0108	CbGeAlD
Theophylline—CYP2E1—kidney—kidney cancer	0.00045	0.0106	CbGeAlD
Theophylline—CYP2E1—cortex of kidney—kidney cancer	0.000438	0.0103	CbGeAlD
Theophylline—CYP3A4—renal system—kidney cancer	0.000375	0.00883	CbGeAlD
Theophylline—CYP2D6—renal system—kidney cancer	0.000369	0.00869	CbGeAlD
Theophylline—CYP3A4—kidney—kidney cancer	0.000362	0.00854	CbGeAlD
Theophylline—CYP2D6—kidney—kidney cancer	0.000356	0.0084	CbGeAlD
Theophylline—Caffeine—CYP1A1—kidney cancer	0.000322	0.0641	CrCbGaD
Theophylline—Hypotension—Everolimus—kidney cancer	0.000279	0.00211	CcSEcCtD
Theophylline—Ventricular extrasystoles—Doxorubicin—kidney cancer	0.000275	0.00208	CcSEcCtD
Theophylline—Diarrhoea—Temsirolimus—kidney cancer	0.000275	0.00207	CcSEcCtD
Theophylline—Anorexia—Erlotinib—kidney cancer	0.000275	0.00207	CcSEcCtD
Theophylline—Insomnia—Everolimus—kidney cancer	0.00027	0.00204	CcSEcCtD
Theophylline—Hyperuricaemia—Doxorubicin—kidney cancer	0.000268	0.00202	CcSEcCtD
Theophylline—Pruritus—Pazopanib—kidney cancer	0.000268	0.00202	CcSEcCtD
Theophylline—Irritability—Capecitabine—kidney cancer	0.000267	0.00202	CcSEcCtD
Theophylline—Urinary retention—Capecitabine—kidney cancer	0.000266	0.00201	CcSEcCtD
Theophylline—Hyperglycaemia—Paclitaxel—kidney cancer	0.000266	0.00201	CcSEcCtD
Theophylline—Dizziness—Temsirolimus—kidney cancer	0.000266	0.002	CcSEcCtD
Theophylline—Convulsion—Sunitinib—kidney cancer	0.000265	0.002	CcSEcCtD
Theophylline—Alopecia—Vincristine—kidney cancer	0.000263	0.00198	CcSEcCtD
Theophylline—Insomnia—Erlotinib—kidney cancer	0.000261	0.00197	CcSEcCtD
Theophylline—Decreased appetite—Vinblastine—kidney cancer	0.000261	0.00197	CcSEcCtD
Theophylline—Decreased appetite—Everolimus—kidney cancer	0.00026	0.00196	CcSEcCtD
Theophylline—Anaphylactic shock—Sorafenib—kidney cancer	0.000259	0.00196	CcSEcCtD
Theophylline—Diarrhoea—Pazopanib—kidney cancer	0.000259	0.00195	CcSEcCtD
Theophylline—Infection—Sorafenib—kidney cancer	0.000258	0.00194	CcSEcCtD
Theophylline—Abdominal pain upper—Capecitabine—kidney cancer	0.000256	0.00193	CcSEcCtD
Theophylline—Vomiting—Temsirolimus—kidney cancer	0.000255	0.00193	CcSEcCtD
Theophylline—Shock—Sorafenib—kidney cancer	0.000255	0.00193	CcSEcCtD
Theophylline—Hypokalaemia—Capecitabine—kidney cancer	0.000255	0.00192	CcSEcCtD
Theophylline—Nervous system disorder—Sorafenib—kidney cancer	0.000254	0.00192	CcSEcCtD
Theophylline—Rash—Temsirolimus—kidney cancer	0.000253	0.00191	CcSEcCtD
Theophylline—Blood uric acid increased—Doxorubicin—kidney cancer	0.000253	0.00191	CcSEcCtD
Theophylline—Dermatitis—Temsirolimus—kidney cancer	0.000253	0.00191	CcSEcCtD
Theophylline—Arrhythmia—Gemcitabine—kidney cancer	0.000252	0.0019	CcSEcCtD
Theophylline—Headache—Temsirolimus—kidney cancer	0.000252	0.0019	CcSEcCtD
Theophylline—Haematuria—Paclitaxel—kidney cancer	0.000251	0.00189	CcSEcCtD
Theophylline—Decreased appetite—Erlotinib—kidney cancer	0.000251	0.00189	CcSEcCtD
Theophylline—Dizziness—Pazopanib—kidney cancer	0.00025	0.00189	CcSEcCtD
Theophylline—Alopecia—Gemcitabine—kidney cancer	0.000249	0.00188	CcSEcCtD
Theophylline—Infection—Sunitinib—kidney cancer	0.000248	0.00187	CcSEcCtD
Theophylline—Anorexia—Sorafenib—kidney cancer	0.000247	0.00187	CcSEcCtD
Theophylline—Dermatitis contact—Doxorubicin—kidney cancer	0.000246	0.00185	CcSEcCtD
Theophylline—Shock—Sunitinib—kidney cancer	0.000245	0.00185	CcSEcCtD
Theophylline—Gastrointestinal pain—Vinblastine—kidney cancer	0.000245	0.00185	CcSEcCtD
Theophylline—Nervous system disorder—Sunitinib—kidney cancer	0.000245	0.00185	CcSEcCtD
Theophylline—Gastrointestinal pain—Everolimus—kidney cancer	0.000244	0.00184	CcSEcCtD
Theophylline—Vomiting—Pazopanib—kidney cancer	0.000241	0.00182	CcSEcCtD
Theophylline—Rash—Pazopanib—kidney cancer	0.000239	0.0018	CcSEcCtD
Theophylline—Nausea—Temsirolimus—kidney cancer	0.000239	0.0018	CcSEcCtD
Theophylline—Dermatitis—Pazopanib—kidney cancer	0.000238	0.0018	CcSEcCtD
Theophylline—Anorexia—Sunitinib—kidney cancer	0.000238	0.0018	CcSEcCtD
Theophylline—Agitation—Vincristine—kidney cancer	0.000238	0.00179	CcSEcCtD
Theophylline—Abdominal pain—Vinblastine—kidney cancer	0.000237	0.00179	CcSEcCtD
Theophylline—Headache—Pazopanib—kidney cancer	0.000237	0.00179	CcSEcCtD
Theophylline—Abdominal pain—Everolimus—kidney cancer	0.000236	0.00178	CcSEcCtD
Theophylline—Body temperature increased—Everolimus—kidney cancer	0.000236	0.00178	CcSEcCtD
Theophylline—Gastrointestinal pain—Erlotinib—kidney cancer	0.000236	0.00178	CcSEcCtD
Theophylline—Infection—Dactinomycin—kidney cancer	0.000235	0.00177	CcSEcCtD
Theophylline—Body temperature increased—Erlotinib—kidney cancer	0.000228	0.00172	CcSEcCtD
Theophylline—Abdominal pain—Erlotinib—kidney cancer	0.000228	0.00172	CcSEcCtD
Theophylline—Coma—Doxorubicin—kidney cancer	0.000227	0.00171	CcSEcCtD
Theophylline—Insomnia—Sunitinib—kidney cancer	0.000226	0.0017	CcSEcCtD
Theophylline—Decreased appetite—Sorafenib—kidney cancer	0.000225	0.0017	CcSEcCtD
Theophylline—Anorexia—Dactinomycin—kidney cancer	0.000225	0.0017	CcSEcCtD
Theophylline—Nausea—Pazopanib—kidney cancer	0.000225	0.0017	CcSEcCtD
Theophylline—Convulsion—Vincristine—kidney cancer	0.000224	0.00169	CcSEcCtD
Theophylline—Hypersensitivity—Vinblastine—kidney cancer	0.000221	0.00167	CcSEcCtD
Theophylline—Hypersensitivity—Everolimus—kidney cancer	0.00022	0.00166	CcSEcCtD
Theophylline—Flushing—Paclitaxel—kidney cancer	0.000219	0.00165	CcSEcCtD
Theophylline—Hyperglycaemia—Capecitabine—kidney cancer	0.000218	0.00165	CcSEcCtD
Theophylline—Decreased appetite—Sunitinib—kidney cancer	0.000217	0.00164	CcSEcCtD
Theophylline—Gastrointestinal pain—Sorafenib—kidney cancer	0.000212	0.0016	CcSEcCtD
Theophylline—Pruritus—Everolimus—kidney cancer	0.000211	0.0016	CcSEcCtD
Theophylline—Anaphylactic shock—Vincristine—kidney cancer	0.000211	0.00159	CcSEcCtD
Theophylline—Arrhythmia—Paclitaxel—kidney cancer	0.000211	0.00159	CcSEcCtD
Theophylline—Infection—Vincristine—kidney cancer	0.00021	0.00158	CcSEcCtD
Theophylline—Phlebitis—Doxorubicin—kidney cancer	0.000209	0.00158	CcSEcCtD
Theophylline—Alopecia—Paclitaxel—kidney cancer	0.000208	0.00157	CcSEcCtD
Theophylline—Nervous system disorder—Vincristine—kidney cancer	0.000207	0.00156	CcSEcCtD
Theophylline—Urticaria—Sorafenib—kidney cancer	0.000206	0.00155	CcSEcCtD
Theophylline—Haematuria—Capecitabine—kidney cancer	0.000206	0.00155	CcSEcCtD
Theophylline—Decreased appetite—Dactinomycin—kidney cancer	0.000205	0.00155	CcSEcCtD
Theophylline—Diarrhoea—Vinblastine—kidney cancer	0.000205	0.00155	CcSEcCtD
Theophylline—Abdominal pain—Sorafenib—kidney cancer	0.000205	0.00155	CcSEcCtD
Theophylline—Body temperature increased—Sorafenib—kidney cancer	0.000205	0.00155	CcSEcCtD
Theophylline—Diarrhoea—Everolimus—kidney cancer	0.000204	0.00154	CcSEcCtD
Theophylline—Gastrointestinal pain—Sunitinib—kidney cancer	0.000204	0.00154	CcSEcCtD
Theophylline—Pruritus—Erlotinib—kidney cancer	0.000204	0.00154	CcSEcCtD
Theophylline—Tension—Paclitaxel—kidney cancer	0.000202	0.00152	CcSEcCtD
Theophylline—Anorexia—Vincristine—kidney cancer	0.000201	0.00152	CcSEcCtD
Theophylline—Anaphylactic shock—Gemcitabine—kidney cancer	0.0002	0.00151	CcSEcCtD
Theophylline—Nervousness—Paclitaxel—kidney cancer	0.000199	0.00151	CcSEcCtD
Theophylline—Infection—Gemcitabine—kidney cancer	0.000199	0.0015	CcSEcCtD
Theophylline—Dizziness—Vinblastine—kidney cancer	0.000198	0.0015	CcSEcCtD
Theophylline—Dizziness—Everolimus—kidney cancer	0.000198	0.00149	CcSEcCtD
Theophylline—Body temperature increased—Sunitinib—kidney cancer	0.000197	0.00149	CcSEcCtD
Theophylline—Abdominal pain—Sunitinib—kidney cancer	0.000197	0.00149	CcSEcCtD
Theophylline—Diarrhoea—Erlotinib—kidney cancer	0.000197	0.00149	CcSEcCtD
Theophylline—Hypotension—Vincristine—kidney cancer	0.000197	0.00149	CcSEcCtD
Theophylline—Nervous system disorder—Gemcitabine—kidney cancer	0.000196	0.00148	CcSEcCtD
Theophylline—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000193	0.00146	CcSEcCtD
Theophylline—Tremor—Paclitaxel—kidney cancer	0.000192	0.00145	CcSEcCtD
Theophylline—Dermatitis exfoliative—Doxorubicin—kidney cancer	0.000191	0.00144	CcSEcCtD
Theophylline—Hypersensitivity—Sorafenib—kidney cancer	0.000191	0.00144	CcSEcCtD
Theophylline—Insomnia—Vincristine—kidney cancer	0.000191	0.00144	CcSEcCtD
Theophylline—Anorexia—Gemcitabine—kidney cancer	0.000191	0.00144	CcSEcCtD
Theophylline—Vomiting—Vinblastine—kidney cancer	0.000191	0.00144	CcSEcCtD
Theophylline—Dizziness—Erlotinib—kidney cancer	0.000191	0.00144	CcSEcCtD
Theophylline—Vomiting—Everolimus—kidney cancer	0.00019	0.00143	CcSEcCtD
Theophylline—Agitation—Paclitaxel—kidney cancer	0.000189	0.00142	CcSEcCtD
Theophylline—Rash—Everolimus—kidney cancer	0.000188	0.00142	CcSEcCtD
Theophylline—Dermatitis—Everolimus—kidney cancer	0.000188	0.00142	CcSEcCtD
Theophylline—Headache—Vinblastine—kidney cancer	0.000188	0.00142	CcSEcCtD
Theophylline—Headache—Everolimus—kidney cancer	0.000187	0.00141	CcSEcCtD
Theophylline—Hypotension—Gemcitabine—kidney cancer	0.000187	0.00141	CcSEcCtD
Theophylline—Abdominal pain—Dactinomycin—kidney cancer	0.000187	0.00141	CcSEcCtD
Theophylline—Body temperature increased—Dactinomycin—kidney cancer	0.000187	0.00141	CcSEcCtD
Theophylline—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000186	0.00141	CcSEcCtD
Theophylline—Hypersensitivity—Sunitinib—kidney cancer	0.000184	0.00139	CcSEcCtD
Theophylline—Decreased appetite—Vincristine—kidney cancer	0.000183	0.00138	CcSEcCtD
Theophylline—Pruritus—Sorafenib—kidney cancer	0.000183	0.00138	CcSEcCtD
Theophylline—Vomiting—Erlotinib—kidney cancer	0.000183	0.00138	CcSEcCtD
Theophylline—Rash—Erlotinib—kidney cancer	0.000182	0.00137	CcSEcCtD
Theophylline—Dermatitis—Erlotinib—kidney cancer	0.000182	0.00137	CcSEcCtD
Theophylline—Palpitations—Paclitaxel—kidney cancer	0.000182	0.00137	CcSEcCtD
Theophylline—Insomnia—Gemcitabine—kidney cancer	0.000181	0.00137	CcSEcCtD
Theophylline—Headache—Erlotinib—kidney cancer	0.000181	0.00136	CcSEcCtD
Theophylline—Flushing—Capecitabine—kidney cancer	0.00018	0.00136	CcSEcCtD
Theophylline—Nausea—Vinblastine—kidney cancer	0.000178	0.00134	CcSEcCtD
Theophylline—Convulsion—Paclitaxel—kidney cancer	0.000178	0.00134	CcSEcCtD
Theophylline—Nausea—Everolimus—kidney cancer	0.000177	0.00134	CcSEcCtD
Theophylline—Diarrhoea—Sorafenib—kidney cancer	0.000177	0.00134	CcSEcCtD
Theophylline—Pruritus—Sunitinib—kidney cancer	0.000177	0.00133	CcSEcCtD
Theophylline—Anxiety—Paclitaxel—kidney cancer	0.000174	0.00132	CcSEcCtD
Theophylline—Decreased appetite—Gemcitabine—kidney cancer	0.000174	0.00131	CcSEcCtD
Theophylline—Hypersensitivity—Dactinomycin—kidney cancer	0.000174	0.00131	CcSEcCtD
Theophylline—Arrhythmia—Capecitabine—kidney cancer	0.000173	0.00131	CcSEcCtD
Theophylline—Gastrointestinal pain—Vincristine—kidney cancer	0.000173	0.0013	CcSEcCtD
Theophylline—Dizziness—Sorafenib—kidney cancer	0.000171	0.00129	CcSEcCtD
Theophylline—Caffeine—ABCB1—kidney cancer	0.000171	0.034	CrCbGaD
Theophylline—Nausea—Erlotinib—kidney cancer	0.000171	0.00129	CcSEcCtD
Theophylline—Alopecia—Capecitabine—kidney cancer	0.000171	0.00129	CcSEcCtD
Theophylline—Diarrhoea—Sunitinib—kidney cancer	0.000171	0.00129	CcSEcCtD
Theophylline—Anaphylactic shock—Paclitaxel—kidney cancer	0.000168	0.00127	CcSEcCtD
Theophylline—Body temperature increased—Vincristine—kidney cancer	0.000167	0.00126	CcSEcCtD
Theophylline—Abdominal pain—Vincristine—kidney cancer	0.000167	0.00126	CcSEcCtD
Theophylline—Infection—Paclitaxel—kidney cancer	0.000167	0.00126	CcSEcCtD
Theophylline—Dizziness—Sunitinib—kidney cancer	0.000165	0.00125	CcSEcCtD
Theophylline—Shock—Paclitaxel—kidney cancer	0.000165	0.00124	CcSEcCtD
Theophylline—Vomiting—Sorafenib—kidney cancer	0.000165	0.00124	CcSEcCtD
Theophylline—Abdominal pain upper—Doxorubicin—kidney cancer	0.000165	0.00124	CcSEcCtD
Theophylline—Nervous system disorder—Paclitaxel—kidney cancer	0.000164	0.00124	CcSEcCtD
Theophylline—Hypokalaemia—Doxorubicin—kidney cancer	0.000164	0.00124	CcSEcCtD
Theophylline—Tachycardia—Paclitaxel—kidney cancer	0.000164	0.00123	CcSEcCtD
Theophylline—Rash—Sorafenib—kidney cancer	0.000164	0.00123	CcSEcCtD
Theophylline—Dermatitis—Sorafenib—kidney cancer	0.000163	0.00123	CcSEcCtD
Theophylline—Headache—Sorafenib—kidney cancer	0.000162	0.00123	CcSEcCtD
Theophylline—Diarrhoea—Dactinomycin—kidney cancer	0.000162	0.00122	CcSEcCtD
Theophylline—Anorexia—Paclitaxel—kidney cancer	0.00016	0.00121	CcSEcCtD
Theophylline—Vomiting—Sunitinib—kidney cancer	0.000159	0.0012	CcSEcCtD
Theophylline—Body temperature increased—Gemcitabine—kidney cancer	0.000158	0.00119	CcSEcCtD
Theophylline—Tremor—Capecitabine—kidney cancer	0.000158	0.00119	CcSEcCtD
Theophylline—Rash—Sunitinib—kidney cancer	0.000157	0.00119	CcSEcCtD
Theophylline—Dermatitis—Sunitinib—kidney cancer	0.000157	0.00119	CcSEcCtD
Theophylline—Hypotension—Paclitaxel—kidney cancer	0.000157	0.00118	CcSEcCtD
Theophylline—Headache—Sunitinib—kidney cancer	0.000156	0.00118	CcSEcCtD
Theophylline—Hypersensitivity—Vincristine—kidney cancer	0.000155	0.00117	CcSEcCtD
Theophylline—Nausea—Sorafenib—kidney cancer	0.000154	0.00116	CcSEcCtD
Theophylline—Insomnia—Paclitaxel—kidney cancer	0.000152	0.00114	CcSEcCtD
Theophylline—Vomiting—Dactinomycin—kidney cancer	0.00015	0.00113	CcSEcCtD
Theophylline—Palpitations—Capecitabine—kidney cancer	0.000149	0.00112	CcSEcCtD
Theophylline—Rash—Dactinomycin—kidney cancer	0.000149	0.00112	CcSEcCtD
Theophylline—Nausea—Sunitinib—kidney cancer	0.000148	0.00112	CcSEcCtD
Theophylline—Decreased appetite—Paclitaxel—kidney cancer	0.000146	0.0011	CcSEcCtD
Theophylline—Diarrhoea—Vincristine—kidney cancer	0.000144	0.00109	CcSEcCtD
Theophylline—Anxiety—Capecitabine—kidney cancer	0.000143	0.00108	CcSEcCtD
Theophylline—Pruritus—Gemcitabine—kidney cancer	0.000142	0.00107	CcSEcCtD
Theophylline—Hyperglycaemia—Doxorubicin—kidney cancer	0.000141	0.00106	CcSEcCtD
Theophylline—Nausea—Dactinomycin—kidney cancer	0.00014	0.00106	CcSEcCtD
Theophylline—Dizziness—Vincristine—kidney cancer	0.00014	0.00105	CcSEcCtD
Theophylline—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000137	0.00103	CcSEcCtD
Theophylline—Diarrhoea—Gemcitabine—kidney cancer	0.000137	0.00103	CcSEcCtD
Theophylline—Infection—Capecitabine—kidney cancer	0.000137	0.00103	CcSEcCtD
Theophylline—Shock—Capecitabine—kidney cancer	0.000135	0.00102	CcSEcCtD
Theophylline—Nervous system disorder—Capecitabine—kidney cancer	0.000135	0.00102	CcSEcCtD
Theophylline—Tachycardia—Capecitabine—kidney cancer	0.000134	0.00101	CcSEcCtD
Theophylline—Vomiting—Vincristine—kidney cancer	0.000134	0.00101	CcSEcCtD
Theophylline—Urticaria—Paclitaxel—kidney cancer	0.000133	0.00101	CcSEcCtD
Theophylline—Rash—Vincristine—kidney cancer	0.000133	0.001	CcSEcCtD
Theophylline—Dermatitis—Vincristine—kidney cancer	0.000133	0.001	CcSEcCtD
Theophylline—Haematuria—Doxorubicin—kidney cancer	0.000133	0.001	CcSEcCtD
Theophylline—Body temperature increased—Paclitaxel—kidney cancer	0.000133	0.001	CcSEcCtD
Theophylline—Abdominal pain—Paclitaxel—kidney cancer	0.000133	0.001	CcSEcCtD
Theophylline—Headache—Vincristine—kidney cancer	0.000132	0.000998	CcSEcCtD
Theophylline—Anorexia—Capecitabine—kidney cancer	0.000131	0.00099	CcSEcCtD
Theophylline—Hypotension—Capecitabine—kidney cancer	0.000129	0.00097	CcSEcCtD
Theophylline—Vomiting—Gemcitabine—kidney cancer	0.000127	0.000961	CcSEcCtD
Theophylline—Rash—Gemcitabine—kidney cancer	0.000126	0.000953	CcSEcCtD
Theophylline—Dermatitis—Gemcitabine—kidney cancer	0.000126	0.000952	CcSEcCtD
Theophylline—Headache—Gemcitabine—kidney cancer	0.000125	0.000947	CcSEcCtD
Theophylline—Nausea—Vincristine—kidney cancer	0.000125	0.000946	CcSEcCtD
Theophylline—Insomnia—Capecitabine—kidney cancer	0.000124	0.000939	CcSEcCtD
Theophylline—Hypersensitivity—Paclitaxel—kidney cancer	0.000124	0.000932	CcSEcCtD
Theophylline—Decreased appetite—Capecitabine—kidney cancer	0.00012	0.000903	CcSEcCtD
Theophylline—Nausea—Gemcitabine—kidney cancer	0.000119	0.000898	CcSEcCtD
Theophylline—Pruritus—Paclitaxel—kidney cancer	0.000119	0.000895	CcSEcCtD
Theophylline—Flushing—Doxorubicin—kidney cancer	0.000116	0.000874	CcSEcCtD
Theophylline—Diarrhoea—Paclitaxel—kidney cancer	0.000115	0.000866	CcSEcCtD
Theophylline—Gastrointestinal pain—Capecitabine—kidney cancer	0.000112	0.000849	CcSEcCtD
Theophylline—Arrhythmia—Doxorubicin—kidney cancer	0.000111	0.000841	CcSEcCtD
Theophylline—Dizziness—Paclitaxel—kidney cancer	0.000111	0.000837	CcSEcCtD
Theophylline—Alopecia—Doxorubicin—kidney cancer	0.00011	0.000832	CcSEcCtD
Theophylline—Urticaria—Capecitabine—kidney cancer	0.000109	0.000825	CcSEcCtD
Theophylline—Body temperature increased—Capecitabine—kidney cancer	0.000109	0.000821	CcSEcCtD
Theophylline—Abdominal pain—Capecitabine—kidney cancer	0.000109	0.000821	CcSEcCtD
Theophylline—Tension—Doxorubicin—kidney cancer	0.000107	0.000805	CcSEcCtD
Theophylline—Vomiting—Paclitaxel—kidney cancer	0.000107	0.000804	CcSEcCtD
Theophylline—Rash—Paclitaxel—kidney cancer	0.000106	0.000798	CcSEcCtD
Theophylline—Dermatitis—Paclitaxel—kidney cancer	0.000106	0.000797	CcSEcCtD
Theophylline—Nervousness—Doxorubicin—kidney cancer	0.000106	0.000796	CcSEcCtD
Theophylline—Headache—Paclitaxel—kidney cancer	0.000105	0.000793	CcSEcCtD
Theophylline—Hypersensitivity—Capecitabine—kidney cancer	0.000101	0.000765	CcSEcCtD
Theophylline—Agitation—Doxorubicin—kidney cancer	9.98e-05	0.000754	CcSEcCtD
Theophylline—Nausea—Paclitaxel—kidney cancer	9.96e-05	0.000751	CcSEcCtD
Theophylline—Pruritus—Capecitabine—kidney cancer	9.73e-05	0.000735	CcSEcCtD
Theophylline—Palpitations—Doxorubicin—kidney cancer	9.6e-05	0.000725	CcSEcCtD
Theophylline—Convulsion—Doxorubicin—kidney cancer	9.41e-05	0.00071	CcSEcCtD
Theophylline—Diarrhoea—Capecitabine—kidney cancer	9.41e-05	0.00071	CcSEcCtD
Theophylline—Anxiety—Doxorubicin—kidney cancer	9.22e-05	0.000696	CcSEcCtD
Theophylline—Dizziness—Capecitabine—kidney cancer	9.1e-05	0.000687	CcSEcCtD
Theophylline—Anaphylactic shock—Doxorubicin—kidney cancer	8.87e-05	0.000669	CcSEcCtD
Theophylline—Infection—Doxorubicin—kidney cancer	8.81e-05	0.000665	CcSEcCtD
Theophylline—Vomiting—Capecitabine—kidney cancer	8.75e-05	0.00066	CcSEcCtD
Theophylline—Shock—Doxorubicin—kidney cancer	8.72e-05	0.000658	CcSEcCtD
Theophylline—Nervous system disorder—Doxorubicin—kidney cancer	8.7e-05	0.000656	CcSEcCtD
Theophylline—Rash—Capecitabine—kidney cancer	8.67e-05	0.000655	CcSEcCtD
Theophylline—Dermatitis—Capecitabine—kidney cancer	8.67e-05	0.000654	CcSEcCtD
Theophylline—Tachycardia—Doxorubicin—kidney cancer	8.65e-05	0.000653	CcSEcCtD
Theophylline—Headache—Capecitabine—kidney cancer	8.62e-05	0.00065	CcSEcCtD
Theophylline—Anorexia—Doxorubicin—kidney cancer	8.45e-05	0.000638	CcSEcCtD
Theophylline—Hypotension—Doxorubicin—kidney cancer	8.29e-05	0.000625	CcSEcCtD
Theophylline—Nausea—Capecitabine—kidney cancer	8.17e-05	0.000617	CcSEcCtD
Theophylline—Insomnia—Doxorubicin—kidney cancer	8.02e-05	0.000605	CcSEcCtD
Theophylline—Decreased appetite—Doxorubicin—kidney cancer	7.71e-05	0.000582	CcSEcCtD
Theophylline—Gastrointestinal pain—Doxorubicin—kidney cancer	7.25e-05	0.000547	CcSEcCtD
Theophylline—Urticaria—Doxorubicin—kidney cancer	7.04e-05	0.000532	CcSEcCtD
Theophylline—Abdominal pain—Doxorubicin—kidney cancer	7.01e-05	0.000529	CcSEcCtD
Theophylline—Body temperature increased—Doxorubicin—kidney cancer	7.01e-05	0.000529	CcSEcCtD
Theophylline—Hypersensitivity—Doxorubicin—kidney cancer	6.53e-05	0.000493	CcSEcCtD
Theophylline—Pruritus—Doxorubicin—kidney cancer	6.27e-05	0.000473	CcSEcCtD
Theophylline—Diarrhoea—Doxorubicin—kidney cancer	6.07e-05	0.000458	CcSEcCtD
Theophylline—Dizziness—Doxorubicin—kidney cancer	5.86e-05	0.000443	CcSEcCtD
Theophylline—Vomiting—Doxorubicin—kidney cancer	5.64e-05	0.000426	CcSEcCtD
Theophylline—Rash—Doxorubicin—kidney cancer	5.59e-05	0.000422	CcSEcCtD
Theophylline—Dermatitis—Doxorubicin—kidney cancer	5.59e-05	0.000422	CcSEcCtD
Theophylline—Headache—Doxorubicin—kidney cancer	5.56e-05	0.000419	CcSEcCtD
Theophylline—Nausea—Doxorubicin—kidney cancer	5.27e-05	0.000398	CcSEcCtD
Theophylline—CYP2C8—Metabolism—SCARB1—kidney cancer	6.84e-06	5.74e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—POMC—kidney cancer	6.81e-06	5.72e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	6.81e-06	5.72e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—CCND1—kidney cancer	6.79e-06	5.7e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—SLC5A5—kidney cancer	6.78e-06	5.69e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—JUN—kidney cancer	6.78e-06	5.69e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—IL2—kidney cancer	6.78e-06	5.69e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—PTGS1—kidney cancer	6.77e-06	5.68e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—MAPK3—kidney cancer	6.76e-06	5.67e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—ST3GAL2—kidney cancer	6.75e-06	5.66e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—BRAF—kidney cancer	6.73e-06	5.65e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—CTNNB1—kidney cancer	6.72e-06	5.64e-05	CbGpPWpGaD
Theophylline—HDAC2—Gene Expression—MAPK3—kidney cancer	6.7e-06	5.62e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—CDKN1B—kidney cancer	6.66e-06	5.6e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—PSMD7—kidney cancer	6.64e-06	5.57e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—CCND1—kidney cancer	6.61e-06	5.55e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—ALDH1A1—kidney cancer	6.6e-06	5.54e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—JUN—kidney cancer	6.59e-06	5.53e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—CDKN1B—kidney cancer	6.59e-06	5.53e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—MYC—kidney cancer	6.57e-06	5.52e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—PTEN—kidney cancer	6.55e-06	5.5e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—SLC2A1—kidney cancer	6.55e-06	5.49e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—CTNNB1—kidney cancer	6.54e-06	5.49e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—IL2—kidney cancer	6.52e-06	5.48e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling by GPCR—MAPK1—kidney cancer	6.52e-06	5.47e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—VEGFA—kidney cancer	6.52e-06	5.47e-05	CbGpPWpGaD
Theophylline—HDAC2—Gene Expression—MYC—kidney cancer	6.51e-06	5.47e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—ITPR2—kidney cancer	6.5e-06	5.46e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—IL2—kidney cancer	6.44e-06	5.41e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—ITPR2—kidney cancer	6.44e-06	5.41e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—MAPK1—kidney cancer	6.43e-06	5.4e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—PTEN—kidney cancer	6.38e-06	5.35e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—CCND1—kidney cancer	6.36e-06	5.34e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.35e-06	5.33e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—JUN—kidney cancer	6.34e-06	5.33e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.34e-06	5.33e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—SLC5A3—kidney cancer	6.32e-06	5.31e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—PGK1—kidney cancer	6.32e-06	5.31e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—VEGFA—kidney cancer	6.32e-06	5.31e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—CTNNB1—kidney cancer	6.3e-06	5.29e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—BCHE—kidney cancer	6.29e-06	5.28e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—CCND1—kidney cancer	6.28e-06	5.27e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—JUN—kidney cancer	6.27e-06	5.26e-05	CbGpPWpGaD
Theophylline—ADORA2A—GPCR downstream signaling—PIK3CA—kidney cancer	6.23e-06	5.23e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—CTNNB1—kidney cancer	6.22e-06	5.22e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—VEGFA—kidney cancer	6.22e-06	5.22e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—MAPK3—kidney cancer	6.22e-06	5.22e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—SLC5A5—kidney cancer	6.21e-06	5.22e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—LDHB—kidney cancer	6.2e-06	5.21e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—MAPK3—kidney cancer	6.17e-06	5.18e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling by GPCR—KRAS—kidney cancer	6.16e-06	5.17e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—PTEN—kidney cancer	6.14e-06	5.15e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—KRAS—kidney cancer	6.07e-06	5.1e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—PTEN—kidney cancer	6.06e-06	5.09e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—MYC—kidney cancer	6.05e-06	5.08e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—RAF1—kidney cancer	6.04e-06	5.07e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—RELA—kidney cancer	6.01e-06	5.05e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—SLC2A1—kidney cancer	6e-06	5.04e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—MYC—kidney cancer	6e-06	5.04e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—MAPK3—kidney cancer	5.98e-06	5.02e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—ERBB2—kidney cancer	5.98e-06	5.02e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.94e-06	4.99e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—ACHE—kidney cancer	5.93e-06	4.98e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—GSTT1—kidney cancer	5.93e-06	4.98e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—CRABP1—kidney cancer	5.92e-06	4.97e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—VEGFA—kidney cancer	5.92e-06	4.97e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—MAPK1—kidney cancer	5.92e-06	4.97e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—MTOR—kidney cancer	5.9e-06	4.95e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—MAPK3—kidney cancer	5.88e-06	4.94e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—ACHE—kidney cancer	5.88e-06	4.93e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—GSTT1—kidney cancer	5.88e-06	4.93e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—MAPK1—kidney cancer	5.87e-06	4.93e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5.82e-06	4.89e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—MYC—kidney cancer	5.82e-06	4.88e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—GSTP1—kidney cancer	5.79e-06	4.86e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—VEGFA—kidney cancer	5.76e-06	4.83e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—POMC—kidney cancer	5.76e-06	4.83e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—MYC—kidney cancer	5.72e-06	4.8e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—MAPK1—kidney cancer	5.69e-06	4.78e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling by GPCR—PIK3CA—kidney cancer	5.66e-06	4.75e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—RAF1—kidney cancer	5.62e-06	4.71e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—SCARB1—kidney cancer	5.61e-06	4.71e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—MAPK3—kidney cancer	5.6e-06	4.7e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—MAPK1—kidney cancer	5.6e-06	4.7e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—RELA—kidney cancer	5.59e-06	4.69e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—KRAS—kidney cancer	5.59e-06	4.69e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—PIK3CA—kidney cancer	5.58e-06	4.68e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—SCARB1—kidney cancer	5.56e-06	4.67e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—ERBB2—kidney cancer	5.56e-06	4.66e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—PTGS1—kidney cancer	5.56e-06	4.66e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—VEGFA—kidney cancer	5.54e-06	4.65e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—KRAS—kidney cancer	5.54e-06	4.65e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.54e-06	4.65e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—CDKN1B—kidney cancer	5.54e-06	4.65e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—ITPR2—kidney cancer	5.51e-06	4.62e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—PTGS1—kidney cancer	5.51e-06	4.62e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—MTOR—kidney cancer	5.48e-06	4.6e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—ABCB1—kidney cancer	5.48e-06	4.6e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—VEGFA—kidney cancer	5.48e-06	4.6e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—GSTP1—kidney cancer	5.46e-06	4.58e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—PSMD7—kidney cancer	5.45e-06	4.57e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—MAPK3—kidney cancer	5.45e-06	4.57e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—MYC—kidney cancer	5.45e-06	4.57e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—IL2—kidney cancer	5.42e-06	4.55e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—PSMD7—kidney cancer	5.4e-06	4.53e-05	CbGpPWpGaD
Theophylline—PDE4C—Signaling Pathways—TP53—kidney cancer	5.4e-06	4.53e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—CA9—kidney cancer	5.38e-06	4.51e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—KRAS—kidney cancer	5.38e-06	4.51e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—MAPK1—kidney cancer	5.33e-06	4.47e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—GSTM1—kidney cancer	5.32e-06	4.47e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—MYC—kidney cancer	5.3e-06	4.45e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—KRAS—kidney cancer	5.29e-06	4.44e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—CCND1—kidney cancer	5.28e-06	4.43e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—JUN—kidney cancer	5.27e-06	4.42e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—MAPK3—kidney cancer	5.24e-06	4.4e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—CTNNB1—kidney cancer	5.23e-06	4.39e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—MAPK1—kidney cancer	5.18e-06	4.35e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—MAPK3—kidney cancer	5.18e-06	4.35e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—ABCB1—kidney cancer	5.17e-06	4.34e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—BCHE—kidney cancer	5.16e-06	4.34e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—CDKN1B—kidney cancer	5.15e-06	4.32e-05	CbGpPWpGaD
Theophylline—HDAC2—Disease—PIK3CA—kidney cancer	5.13e-06	4.31e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—BCHE—kidney cancer	5.12e-06	4.3e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—SLC5A5—kidney cancer	5.1e-06	4.28e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—MYC—kidney cancer	5.1e-06	4.28e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—PTEN—kidney cancer	5.1e-06	4.28e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—PIK3CA—kidney cancer	5.09e-06	4.27e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.08e-06	4.26e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.08e-06	4.26e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—SLC5A5—kidney cancer	5.06e-06	4.25e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—CYP1A1—kidney cancer	5.04e-06	4.23e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—MYC—kidney cancer	5.04e-06	4.23e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—IL2—kidney cancer	5.04e-06	4.23e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—KRAS—kidney cancer	5.03e-06	4.22e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—ACHE—kidney cancer	5.02e-06	4.22e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—GSTT1—kidney cancer	5.02e-06	4.22e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—GSTM1—kidney cancer	5.02e-06	4.21e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—GSTP1—kidney cancer	5.01e-06	4.2e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—MAPK1—kidney cancer	4.99e-06	4.19e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—PIK3CA—kidney cancer	4.94e-06	4.15e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—MAPK1—kidney cancer	4.93e-06	4.14e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—SLC2A1—kidney cancer	4.93e-06	4.14e-05	CbGpPWpGaD
Theophylline—ADORA2B—Signaling Pathways—TP53—kidney cancer	4.93e-06	4.14e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—CCND1—kidney cancer	4.91e-06	4.12e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—JUN—kidney cancer	4.9e-06	4.11e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—KRAS—kidney cancer	4.9e-06	4.11e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—SLC2A1—kidney cancer	4.88e-06	4.1e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—CTNNB1—kidney cancer	4.86e-06	4.08e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—PIK3CA—kidney cancer	4.86e-06	4.08e-05	CbGpPWpGaD
Theophylline—PDE3B—Signaling Pathways—TP53—kidney cancer	4.78e-06	4.01e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—SCARB1—kidney cancer	4.75e-06	3.99e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.74e-06	3.98e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—PTEN—kidney cancer	4.74e-06	3.98e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—ABCB1—kidney cancer	4.74e-06	3.98e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—KRAS—kidney cancer	4.71e-06	3.96e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—PTGS1—kidney cancer	4.71e-06	3.95e-05	CbGpPWpGaD
Theophylline—PDE4D—Signaling Pathways—TP53—kidney cancer	4.7e-06	3.94e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—KRAS—kidney cancer	4.66e-06	3.91e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—PIK3CA—kidney cancer	4.62e-06	3.88e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—PSMD7—kidney cancer	4.61e-06	3.87e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—VEGFA—kidney cancer	4.6e-06	3.86e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—GSTM1—kidney cancer	4.6e-06	3.86e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—PTGS2—kidney cancer	4.59e-06	3.86e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—CRABP1—kidney cancer	4.57e-06	3.84e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—PIK3CA—kidney cancer	4.5e-06	3.78e-05	CbGpPWpGaD
Theophylline—PDE4A—Signaling Pathways—TP53—kidney cancer	4.47e-06	3.75e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—BCHE—kidney cancer	4.37e-06	3.67e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—CYP1A1—kidney cancer	4.36e-06	3.66e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—MAPK3—kidney cancer	4.35e-06	3.66e-05	CbGpPWpGaD
Theophylline—PDE3A—Signaling Pathways—TP53—kidney cancer	4.35e-06	3.65e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—PIK3CA—kidney cancer	4.33e-06	3.63e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—SLC5A5—kidney cancer	4.32e-06	3.63e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—VEGFA—kidney cancer	4.28e-06	3.59e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—PIK3CA—kidney cancer	4.28e-06	3.59e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—ITPR2—kidney cancer	4.25e-06	3.57e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—MYC—kidney cancer	4.24e-06	3.56e-05	CbGpPWpGaD
Theophylline—ADORA1—Signaling Pathways—TP53—kidney cancer	4.19e-06	3.52e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—SLC2A1—kidney cancer	4.17e-06	3.5e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—MAPK1—kidney cancer	4.14e-06	3.48e-05	CbGpPWpGaD
Theophylline—PDE4B—Signaling Pathways—TP53—kidney cancer	4.14e-06	3.47e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.13e-06	3.47e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—GSTP1—kidney cancer	4.11e-06	3.45e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—GSTP1—kidney cancer	4.07e-06	3.42e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.05e-06	3.4e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—MAPK3—kidney cancer	4.05e-06	3.4e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—PTEN—kidney cancer	4.01e-06	3.36e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—MYC—kidney cancer	3.94e-06	3.31e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—KRAS—kidney cancer	3.91e-06	3.29e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.91e-06	3.28e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—ABCB1—kidney cancer	3.89e-06	3.27e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—ACHE—kidney cancer	3.88e-06	3.25e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—GSTT1—kidney cancer	3.88e-06	3.25e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—ABCB1—kidney cancer	3.86e-06	3.24e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—MAPK1—kidney cancer	3.85e-06	3.23e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—GSTM1—kidney cancer	3.78e-06	3.17e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—POMC—kidney cancer	3.76e-06	3.16e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—GSTM1—kidney cancer	3.74e-06	3.14e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—SCARB1—kidney cancer	3.67e-06	3.08e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—KRAS—kidney cancer	3.64e-06	3.05e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—PTGS1—kidney cancer	3.63e-06	3.05e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—PIK3CA—kidney cancer	3.6e-06	3.02e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.58e-06	3.01e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.58e-06	3.01e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—PSMD7—kidney cancer	3.56e-06	2.99e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—CYP1A1—kidney cancer	3.55e-06	2.98e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—POMC—kidney cancer	3.55e-06	2.98e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.53e-06	2.96e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—GSTP1—kidney cancer	3.48e-06	2.92e-05	CbGpPWpGaD
Theophylline—HDAC2—Signaling Pathways—TP53—kidney cancer	3.48e-06	2.92e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—BCHE—kidney cancer	3.38e-06	2.83e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—PIK3CA—kidney cancer	3.34e-06	2.81e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.34e-06	2.8e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—ABCB1—kidney cancer	3.3e-06	2.77e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—POMC—kidney cancer	3.25e-06	2.73e-05	CbGpPWpGaD
Theophylline—ADORA2A—Signaling Pathways—TP53—kidney cancer	3.23e-06	2.71e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.22e-06	2.7e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—GSTM1—kidney cancer	3.2e-06	2.69e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—CYP1A1—kidney cancer	3.03e-06	2.55e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—PTGS2—kidney cancer	3e-06	2.52e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.92e-06	2.45e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—PTGS2—kidney cancer	2.83e-06	2.37e-05	CbGpPWpGaD
Theophylline—CYP1B1—Metabolism—PIK3CA—kidney cancer	2.83e-06	2.37e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—GSTP1—kidney cancer	2.69e-06	2.26e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—POMC—kidney cancer	2.67e-06	2.24e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—POMC—kidney cancer	2.65e-06	2.22e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—PTEN—kidney cancer	2.62e-06	2.2e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—PTGS2—kidney cancer	2.59e-06	2.18e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—ABCB1—kidney cancer	2.54e-06	2.13e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.49e-06	2.09e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—GSTM1—kidney cancer	2.47e-06	2.07e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—PTEN—kidney cancer	2.47e-06	2.07e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.34e-06	1.96e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—PTEN—kidney cancer	2.26e-06	1.9e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—POMC—kidney cancer	2.26e-06	1.9e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—PTGS2—kidney cancer	2.13e-06	1.79e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—PTGS2—kidney cancer	2.11e-06	1.77e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—PTEN—kidney cancer	1.86e-06	1.56e-05	CbGpPWpGaD
Theophylline—CYP2E1—Metabolism—PIK3CA—kidney cancer	1.85e-06	1.55e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—PTEN—kidney cancer	1.84e-06	1.55e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—PTGS2—kidney cancer	1.8e-06	1.51e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—POMC—kidney cancer	1.74e-06	1.46e-05	CbGpPWpGaD
Theophylline—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.74e-06	1.46e-05	CbGpPWpGaD
Theophylline—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.6e-06	1.34e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—PTEN—kidney cancer	1.57e-06	1.32e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—PTGS2—kidney cancer	1.39e-06	1.17e-05	CbGpPWpGaD
Theophylline—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.31e-06	1.1e-05	CbGpPWpGaD
Theophylline—CYP2C9—Metabolism—PIK3CA—kidney cancer	1.3e-06	1.09e-05	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—PTEN—kidney cancer	1.21e-06	1.02e-05	CbGpPWpGaD
Theophylline—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.11e-06	9.31e-06	CbGpPWpGaD
Theophylline—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.56e-07	7.19e-06	CbGpPWpGaD
